AstraZeneca PLC (AZN) EPS Estimated At $0.44

October 14, 2018 - By Darrin Black

AstraZeneca PLC (NYSE:AZN) Logo

Analysts expect AstraZeneca PLC (NYSE:AZN) to report $0.44 EPS on November, 8.They anticipate $0.68 EPS change or 60.71 % from last quarter’s $1.12 EPS. AZN’s profit would be $1.10B giving it 21.11 P/E if the $0.44 EPS is correct. After having $0.69 EPS previously, AstraZeneca PLC’s analysts see -36.23 % EPS growth. The stock decreased 1.30% or $0.49 during the last trading session, reaching $37.15. About 3.69 million shares traded. AstraZeneca PLC (NYSE:AZN) has risen 13.38% since October 14, 2017 and is uptrending. It has underperformed by 2.24% the S&P500.

AstraZeneca PLC (NYSE:AZN) Ratings Coverage

Among 2 analysts covering AstraZeneca (NYSE:AZN), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. AstraZeneca had 2 analyst reports since June 12, 2018 according to SRatingsIntel. The rating was downgraded by Jefferies to “Hold” on Thursday, August 16. The rating was maintained by Morningstar with “Hold” on Tuesday, June 12.

AstraZeneca PLC discovers, develops, makes, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide. The company has market cap of $92.96 billion. The Company’s marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases. It has a 35.21 P/E ratio. The companyÂ’s marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalent and Synagis for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases.

More important recent AstraZeneca PLC (NYSE:AZN) news were published by: Seekingalpha.com which released: “PhaseBio IPO: Data To Be Released In 2018 And 2020” on October 12, 2018, also Seekingalpha.com published article titled: “PhaseBio on deck for IPO”, Fool.com published: “3 Big Pharma Stocks Racing Along the Road to China” on October 12, 2018. More interesting news about AstraZeneca PLC (NYSE:AZN) was released by: Seekingalpha.com and their article: “AstraZeneca aims to build lead in China” with publication date: September 19, 2018.

AstraZeneca PLC (NYSE:AZN) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>